The International Continence Society defines overactive bladder (OAB) as the presence of “urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of urinary tract infection (UTI) or other obvious pathology.”
Implications of Big Data Analysis in the Real-World Setting: The Case of Overactive Bladder Treatment
A key measure of the 2010 Affordable Care Act is the improvement of care transitions within the healthcare continuum. Optimal medication utilization is important during these care transitions.
A Systematic Approach to Medication Therapy Management in Elderly Patients with Chronic Diseases Can Improve Outcomes
Bevacizumab has shown superiority in improving overall survival for patients with cancer, but because of the increased risk for thromboembolic events leads to higher mortality, such superiority may be affected. Here is a examination of the literature for such adverse events.
Better Patient Education Needed Regarding Thromboembolic Events Risk in Patients with Cancer
Automated dispensing cabinets (ADCs) have helped in monitoring quality-assurance data, particularly related to dispensation and diversion of controlled substances. This article describes the characteristics of controlled substance discrepancies found at a Level I trauma hospital among Medicare patients and the use of an ADC at the medical facility.
Dramatic Increase in Misuse of Controlled Substances a Concern for All Stakeholders
Chronic obstructive pulmonary disease (COPD) is characterized by persistent, progressive airflow limitation that is not fully reversible. This study analyzed the effects of early versus delayed initiation of roflumilast treatment after a hospital or emergency department discharge resulting from COPD exacerbation.
Continuing Challenges in COPD Management, Despite Its Prevalence and High Economic Burden
Hepatitis C is a disease of the liver resulting from infection by the hepatitis C virus (HCV). HCV infection is blood-borne and can result in an acute illness, with severity ranging from mild (little or no symptoms) to severe (symptoms requiring hospitalization).
Taking Steps to Cure Chronic Hepatitis C Virus Infection
Health professionals are increasingly encouraged to involve patients in their treatment decisions, recognizing that patients are experts in terms of their preferences and have unique knowledge of their own health.
Challenges in the Assessment of Patient Preferences among RA Therapies
The new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can have significant budget effects, depending on the breadth of the US Food and Drug Administration (FDA)’s approved labeling. American Health & Drug Benefits asked Stephen Gorshow, MD, and James T. Kenney, RPh, MBA, to participate in a teleconference to better understand how payers are approaching the management of these agents.
Major pharmaceutical companies currently devote substantial resources to detailing activities for their major products, with estimated annual spending of $7 billion to $20 billion.
Improving Patient Outcomes and Drug Prescribing Cost-Effectiveness Through Academic Detailing
Many believe that proprotein convertase subtil­isin/kexin type 9 (PCSK9) inhibitors are the pharmacotherapeutic innovation of the decade for prevention of cardiovascular (CV) events.
Page 3 of 11
Results 21 - 30 of 107
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME